Drug intelligence / Profile preview

INAVAC

Development stage: Phase 3
Lead developer: Universitas Airlangga
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

INAVAC is an inactivated COVID-19 vaccine developed in Indonesia. It is made from SARS-CoV-2 virus isolated from a patient in Surabaya, composed with aluminum hydroxide gel, tween 80, and L-histidine. The vaccine was developed by a research team from Airlangga University (Unair) in collaboration with PT Biotis Pharmaceutical Indonesia as the production facility provider. INAVAC is administered as a 2-dose schedule, intramuscularly, with a 28-day interval between doses.

Brand names: INAVACVaksin Merah Putih
Other names: Vaksin Merah PutihRed and White Vaccine

Beyond the preview

Go deeper on INAVAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INAVAC.

Explore the full profile